New diabetes drug shows promise for weight loss in real-world study
NCT ID NCT06427083
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study tracks 200 adults with type 2 diabetes who are prescribed enavogliflozin (alone or with other diabetes drugs) to see how much weight they lose over 24 weeks. Researchers measure changes in body weight and BMI at 12 and 24 weeks. The goal is to understand the drug's real-world effectiveness and safety for weight management in primary care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Kyung Hee University Medical Center
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.